Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
Lene Hoimark, Torben Laursen, Jørgen RungbyDepartment of Biomedicine – Pharmacology and Clinical Pharmacology, Aarhus University Hospital and Aarhus University, Aarhus, DenmarkBackground: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme...
Enregistré dans:
Auteurs principaux: | Hoimark L, Laursen T, Rungby J |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9e9a08294b40482b99b4feb3ff8beb1c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
par: Petersen AB, et autres
Publié: (2013) -
Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
par: Scott D
Publié: (2013) -
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
par: Gallwitz B
Publié: (2013) -
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
par: Mann KV, et autres
Publié: (2014) -
Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
par: Saunders WB, et autres
Publié: (2016)